DEPO - Depomed, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
5.06
-0.09 (-1.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.15
Open5.18
Bid4.83 x 100
Ask5.35 x 700
Day's Range5.03 - 5.37
52 Week Range4.93 - 24.50
Volume961,944
Avg. Volume1,715,203
Market Cap318.72M
Beta0.80
PE Ratio (TTM)-2.83
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit23 hours ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    Depomed Inc NASDAQ/NGS:DEPO

  • Barrons.com4 days ago

    Valeant: A Problem…Or Just More Noise?

    October has been relatively quiet for Valeant Pharmaceuticals Internation (VRX), with little in the way of attention getting news. Yes, there have been some small successes in drug trials, and even a positive note from a Deutsche Bank analyst. Today, however, Valeant's stock has more than doubled its October loss after Wells Fargo's David Maris raised concerns about a lawsuit filed by Depomed (DEPO) over an alleged $20 million in unpaid royalties: In the grand scheme of Valeant’s issues, an unpaid $20 million bill barely rises to the level of investor concern.

  • Capital Cube4 days ago

    ETFs with exposure to Depomed, Inc. : October 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Depomed, Inc. Here are 5 ETFs with the largest exposure to DEPO-US. Comparing the performance and risk of Depomed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    Depomed Inc NASDAQ/NGS:DEPO

  • Can Depomed Inc (DEPO) Improve Your Portfolio Returns?
    Simply Wall St.15 days ago

    Can Depomed Inc (DEPO) Improve Your Portfolio Returns?

    If you are a shareholder in Depomed Inc’s (NASDAQ:DEPO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    Depomed Inc NASDAQ/NGS:DEPO

  • Capital Cube25 days ago

    ETFs with exposure to Depomed, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Depomed, Inc. Here are 5 ETFs with the largest exposure to DEPO-US. Comparing the performance and risk of Depomed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
    Capital Cube26 days ago

    Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017

    Categories: Yahoo FinanceGet free summary analysis Depomed, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Depomed, Inc. – BioDelivery Sciences International, Inc., Ironwood Pharmaceuticals, Inc. Class A, Mallinckrodt Plc, Insys Therapeutics, Inc., Merck & Co., Inc., Cara Therapeutics Inc and Pfizer Inc. (BDSI-US, IRWD-US, ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Depomed Inc.

    Depomed Inc NASDAQ/NGS:DEPO

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Depomed Inc.

    Depomed Inc NASDAQ/NGS:DEPO

  • What Does Depomed Inc’s (DEPO) Share Price Indicate?
    Simply Wall St.last month

    What Does Depomed Inc’s (DEPO) Share Price Indicate?

    Depomed Inc (NASDAQ:DEPO), a pharmaceuticals, biotechnology and life sciences company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising toRead More...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • The Wall Street Journal2 months ago

    [$$] Companies Face Record Number of Shareholder Lawsuits

    This year has seen a historic number of class-action securities lawsuits. Law firms are increasingly bringing securities cases targeting business disruptions or disasters, failed pharmaceutical trials ...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DEPO earnings conference call or presentation 7-Aug-17 8:30pm GMT

    Q2 2017 Depomed Inc Earnings Call

  • Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : August 11, 2017
    Capital Cube2 months ago

    Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : August 11, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Depomed, Inc. a score of 28. Our analysis is based on comparing Depomed, Inc. with the following peers – BioDelivery Sciences International, Inc., Ironwood Pharmaceuticals, Inc. Class A, Mallinckrodt Plc, Insys Therapeutics, Inc., Pfizer Inc., Cara Therapeutics Inc, Galena Biopharma, Inc., Merck & Co., Inc. and Johnson ... Read more (Read more...)

  • IHS Markit Score Update: Drop in demand for ETFs holding Depomed Inc is a negative sign for its shares
    Markit2 months ago

    IHS Markit Score Update: Drop in demand for ETFs holding Depomed Inc is a negative sign for its shares

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DEPO totaled $99 million.

  • Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
    Motley Fool2 months ago

    Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today

    These stocks helped drag the market lower. Find out why.

  • TheStreet.com2 months ago

    Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

    FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8.

  • Benzinga2 months ago

    The Market In 5 Minutes

    IN THE NEWS Benzinga Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) lost more than 58 percent of their value Monday after the company reported disappointing results from its phase 2 STAR 1 clinical ...

  • Associated Press2 months ago

    Depomed reports 2Q loss

    The Newark, California-based company said it had a loss of 43 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 8 cents per share. The results matched Wall Street ...

  • Capital Cube2 months ago

    ETFs with exposure to Depomed, Inc. : August 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Depomed, Inc. Here are 5 ETFs with the largest exposure to DEPO-US. Comparing the performance and risk of Depomed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : July 28, 2017
    Capital Cube3 months ago

    Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : July 28, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Depomed, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Reuters3 months ago

    U.S. Senator expands opioid probe to distributors, drugmakers

    U.S. Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors. The investigation comes at a time when lawmakers and regulators take steps to combat the epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according to the U.S. Centers for Disease Control and Prevention. McCaskill requested for documents and information from opioid manufacturers Mallinckrodt Plc, Endo International Plc, Teva Pharmaceutical and Allergan Plc.